Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00142545 · ClinicalTrials.gov registry record · Phase 3
Long Term Safety and Efficacy of SC Apomorphine in Treatment of "Off" Episodes in Late-Stage Parkinson's Disease
A Phase 3 study, sponsored by Mylan Bertek Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 800
- Enrollment target
NCT00142545: Completed Phase 3 study, sponsored by Mylan Bertek Pharmaceuticals.
NCT00142545 is a Phase 3 study that has completed, run by Mylan Bertek Pharmaceuticals. The registered enrollment target is 800 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00142545, a Phase 3 study, has completed, sponsored by Mylan Bertek Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 800 participants
- Enrollment target
Study Summary
The current protocol is designed to satisfy the need for a compassionate use treatment protocol as well as for a long-term open label follow-up study.
Interventions
- DRUG apomorphine HCl injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 800 participants |
| Start Date | 1999-07 |
| Est. Completion | 2005-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00142545
The ClinicalTrials.gov registry entry for NCT00142545 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 800 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mylan Bertek Pharmaceuticals, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which apomorphine HCl injection is the first listed.
NCT00142545 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00142545 about?
NCT00142545 is a clinical study titled "Long Term Safety and Efficacy of SC Apomorphine in Treatment of "Off" Episodes in Late-Stage Parkinson's Disease". The current protocol is designed to satisfy the need for a compassionate use treatment protocol as well as for a long-term open label follow-up study.
What is the current status of trial NCT00142545?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 800 participants. The study started on 1999-07. Estimated completion is 2005-07.
What interventions are being tested in trial NCT00142545?
The interventions under investigation include: apomorphine HCl injection (DRUG).
Who is sponsoring clinical trial NCT00142545?
This trial is sponsored by Mylan Bertek Pharmaceuticals, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.